OPHTHALMIC PREPARATIONS OF MUSCARINIC AGONIST AND METHODS OF USE

Abstract

The present invention provides stable topical ophthalmic preparations of muscarinic agonist for the treatment of dry eye disease. The composition can include a polyunsaturated fatty acid.

Claims

1) A stable aqueous topical ophthalmic composition comprising about 0.1% to 10% of cevimeline at a neutral pH range of pH 6-9, and one or more pharmaceutically acceptable excipients.

2) The composition of claim 1, wherein cevimeline is present as the free base form, salt form, or a combination of free base and salt form.

3) The composition of claim 1 or 2, wherein the cevimeline is present at a concentration of about 0.1% to about 10% w/v, about 0.5% to about 5% w/v, or about 0.2% to about 2% w/v.

4) The composition of any one of the above claims further comprising at least one PUFA.

5) The composition of claim 4, wherein the PUFA is present at a concentration of about 0.1%-to about 10% w/v, about 0.5% to about 5% w/v, or about 0.2% to about 2% w/v.

6) The composition of claim 4 or 5, wherein said PUFA comprises about 12 to about 26 carbon atoms per molecule.

7) The composition of claim 4, 5, or 6, wherein said PUFA is selected from the group consisting of omega-3 fatty acid, omega-6 fatty acid, and a mixture thereof.

8) The composition of claim 4, 5, 6, or 7, wherein said PUFA is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), gamma-linolenic acid (GLA), and a mixture thereof.

9) The composition of any one of the above claims further comprising buffering agent, tonicity modifier, and water.

10) The composition of claim 9 optionally further comprising one or more of at least one preservative(s), at least one chelating agent(s), at least one viscosity-modifying agent(s), at least one surfactant(s), at least one solubilizer(s), and/or at least one antioxidant(s).

11) The composition of any one of the above claims, wherein said composition has an osmolality in the range of about 200 to about 400 mOsm/L and a pH in the range of about 6 to about 9.

12) The composition of any one of the above claims further comprising one or more other active ingredient(s) selected from the group consisting of a) at least one steroid; b) at least one immunomodulator (immunosuppressant); c) at least one hormone (androgen); d) a lymphocyte function associated antigen-1 (LFA-1) antagonist; and f) at least one active ingredient effective for treating Meibomian gland dysfunction.

13) The composition of claim 12, wherein a) said steroid is present at a concentration in the range of about 0.1% to about 1% w/v; b) said immunomodulator is present at a concentration in the range of about 0.05% to about 0.1% w/v; c) said hormone is present at a concentration in the range of about 0.01% to about 0.5% w/v; or d) said secretagogue is present at a concentration in the range of about 1% to about 5% w/v; or e) said lymphocyte function associated antigen-1 (LFA-1) antagonist in the range of about 1% to about 5% w/v.

14) The composition of claim 12 or 13, wherein a) said steroid is loteprednol etabonate, prednisolone acetate, fluticasone, or a combination thereof; b) said immunomodulator is cyclosporine, tacrolimus, sirlolimus, or a combination thereof; c) said hormone is testosterone, estrogen, or a combination thereof; d) said secretagogue is rebamipide, diquafosol, or a combination thereof; or e) said lymphocyte function associated antigen-1 (LFA-1) antagonist is lifitegrast.

15) The composition of any one of the above claims, wherein said composition excludes an ointment composition, cream composition, plaster composition, paste composition, and non-aqueous composition.

16) The composition of any one of the above claims, wherein said composition excludes insulin, IGF (insulin-like growth factor), somatomedin C, and cycloplegic agent.

17) The composition of any one of the above claims, wherein cevimeline is replaced with pilocarpine, aceclidine, acetylcholine, bethanechol, carbachol, oxotremorine, or any muscarinic receptor agonist that has therapeutic effect to treat dry eye disease.

18) An ophthalmically acceptable ion-pair comprising a muscarinic receptor agonist amine drug and a fatty acid component selected from the group consisting of polyunsaturated fatty acids (PUFA) for the treatment of dry eye disease.

19) The ion-pair of claim 18, wherein the molar ratio of PUFA to muscarinic receptor agonist amine drug is in the range of about 2:1 to 1:2, or about 1:1.

20) The ion-pair of claim 18 or 19, wherein a) said PUFA comprises about 12 to about 26 carbon atoms per molecule or a mixture thereof; b) said PUFA is selected from the group consisting of omega-3 fatty acid, omega-6 fatty acid, or a combination thereof; or c) said PUFA is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), gamma-linolenic acid (GLA), or a mixture thereof.

21) The composition of any one of claims 1-17 further comprising the ion-pair of any one of claims 18-20.

22) A method of treating a dry eye disorder, disease or condition comprising topically administering to the eye of a subject in need thereof, a composition according to any one of claims 1-17.

23) A method of treating a dry eye disorder, disease or condition comprising topically administering to the eye of a subject in need thereof, an ion-pair according to any one of claims 18-20.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0050] The ophthalmic composition comprises at least one MRA and one or more pharmaceutically acceptable excipients in an aqueous vehicle, meaning a primarily water-containing vehicle. The aqueous vehicle can be present as purified water, lacrimal fluid and/or autologous serum.

[0051] The invention is based in part on the discovery that cevimeline can be prepared as a stable and comfortable neutral pH composition for ocular use particularly for dry eye disease treatment. Said formulation has a neutral pH and suitable to the eye following topical administration. The MRA, e.g. cevimeline, containing composition exhibits high storage stability at room temperature, i.e. from 15-25° C. In some embodiments, the MRA undergoes less than 3% w of degradation during 18-24 months storage period at 25° C.

[0052] The invention features novel topical ophthalmic composition(s) comprising an effective amount of cevimeline, as free base and/or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable preparation. In particular embodiments, the invention provides stable ophthalmic preparations of cevimeline as the only active agent in the preparations. The invention also features ophthalmic preparations of cevimeline in combination with one or more additional active ingredients selected from cyclosporine, loteprednol etabonate, testosterone, diquafosol or its salts, and/or lifitegrast.

[0053] In preparing the ophthalmic composition, the PUFA can be added as a separate ingredient from the MRA. In some embodiments, the PUFA is present at a concentration of about 0.1%-10.0% w/v, or more preferably 0.2%-5.0% w/v, or more preferably 0.5%-2.0% w/v. Alternatively, the PUFA is included as part to form ion pair between MRA and the PUFA. The molar ratio of PUFA to MRA is in the range of about 2:1 to about 1:2, or about 1:1.

[0054] The present invention also provides a pharmaceutically stable topical ophthalmic preparation comprising polyunsaturated fatty acid (PUFA) ion paired with muscarinic agonist amine drug for the treatment of ocular pathologies, in particular for dry eye disease.

[0055] The PUFA can be selected from the group consisting of essential fatty acids containing more than one double bond in their backbone. Exemplary suitable PUFA's include omega-3 fatty acids and omega-6 fatty acid. Exemplary omega-3 fatty acids include alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and other known homologs and derivatives of such acids. Exemplary omega-6 fatty acids include linoleic acid (LA), gamma-linolenic acid (GLA), and other known homologs and derivatives of such acids.

[0056] In some embodiments, the invention provides ophthalmic preparations comprising an effective amount of cevimeline and cyclosporine. Such preferred combination preparations are effective in further mitigating the signs and symptoms of dry eye disease.

[0057] In another embodiment, the invention provides an ophthalmic preparation comprising an effective amount of cevimeline and testosterone.

[0058] In another embodiment, the invention provides an ophthalmic preparation comprising an effective amount of cevimeline and diquafosol.

[0059] In another embodiment, the invention provides an ophthalmic preparation comprising an effective amount of cevimeline and lifitegrast.

[0060] In another embodiment, the invention provides a stable ophthalmic preparation of PUFA ion paired with cevimeline. In certain embodiments, cevimeline is present in the preparation at a concentration of about 0.1% to about 10.0% (w/v), or any value within said range.

[0061] The stability, comfort, safety, and efficacy of the ophthalmic preparations of the invention could not have been predicted by one skilled in the art.

[0062] Pharmaceutical compositions comprising an effective amount of cevimeline along or in combination of loteprednol etabonate, cyclosporine, testosterone, diquafosol or its salts which are formulated for ophthalmic administration are disclosed herein. The preparations are for treating dry eye disease.

[0063] A preparation for ophthalmic administration is formulated such that it can be administered topically to the eye. The comfort should be maximized as much as possible, although sometimes preparation considerations (e.g. drug stability) may necessitate less than optimal comfort.

[0064] Unless indicated otherwise, all ingredient concentrations are presented in units of weight/volume (% w/v).

[0065] In certain compositions, the concentration of cevimeline is in the range of about 0.1% to about 10.0%.

[0066] In certain compositions, the concentration of cevimeline is from 0.1% to 10.0% and loteprednol etabonate is from 0.1% to 0.5%.

[0067] In certain compositions the concentration of cevimeline is in the range of about 0.1% to about 10.0% and the concentration of cyclosporine is in the range of about 0.05% to about 0.1%, about 0.01% to about 0.1%, or about 0.03% to about 0.1%.

[0068] In certain compositions, the concentration of cevimeline is in the range of about 0.1% to about 10.0% and concentration of testosterone is in the range of about 0.01% to about 0.1%.

[0069] In certain compositions, the concentration of cevimeline is in the range of about 0.1% to about 10.0% and the concentration of diquafosol is in the range of about 1% to about 3.0%. or about 1% to about 5% w/v

[0070] In certain embodiment, the ophthalmic composition of present invention has a pH from about 6 to about 9 or preferably from about 7 to about 8. The pH of lacrimal fluid is about 7.4. It is understood that acid or base can be used to adjust the pH of the composition as needed.

[0071] The ophthalmic composition may or may not be isotonic. In some embodiments, the ophthalmic composition of present invention has an osmolality from about 200 to about 400 milliosmoles/liter (mOsm/L) or preferably from about 240 to about 360 mOsm/L. In some embodiments, the composition comprises about 0.9% NaCl, or about 0.7% to about 1.5% NaCl.

[0072] A pharmaceutical composition (formulation) according to the present invention may include one or more pharmaceutically acceptable excipients selected from the group consisting of buffering agent(s), tonicity-adjusting agent(s), surfactant(s), solubilizer(s), viscosity-modifying (enhancing) agent(s), pH-adjusting agent(s) (e.g. acid and/or base), chelating agent(s), preservative(s), antioxidant(s), or a combination of any two or more thereof.

[0073] Exemplary buffering agents include, but are not limited to, phosphate salt, borate salt, citrate salt, acetate salt, carbonate salt, bicarbonate salt, borate-polyol complexes, boric acid, sodium acetate, amino acid, Tris, bicarbonate, BIS-Tris, or salt thereof, combinations thereof and the like. The buffering agent(s) can be present in an amount ranging from about 5-200 mM, or about 10-100 mM.

[0074] Examples of tonicity-adjusting agents include, but are not limited to mannitol, sorbitol, potassium chloride, sodium chloride, xylitol, glycerin, trehalose, taurine, erythritol, combinations thereof, and the like. The amount of tonicity-adjusting agent in the composition will be that amount required to render the composition isotonic, e.g. isotonic with lacrimal fluid.

[0075] Examples of surfactants include, but are not limited to poloxamers, tyloxapol, polysorbate such as polysorbate 80, polysorbate 20, polyoxyethylene castor oil derivatives, sorbitan esters, combinations thereof and the like. The composition typically comprises less than 5%, less than 2% or less than 1% of surfactant. Some embodiments of the invention exclude surfactant.

[0076] Examples of solubilizers include, but are not limited to solutol, soluplus, cyclodextrin(s), vegetable oils, combinations thereof, and the like. The composition typically comprises less than 5%, less than 2% or less than 1% of solubilizer(s). Some embodiments of the invention exclude solubilizer(s).

[0077] Viscosity-modifying (enhancing) agents are hydrophilic polymers that are added to ocular solutions for two main reasons: (1) to control the rate at which the drop flows out of the container (and thus enhance ease of application); and, more importantly, (2) to control the residence time of the solution within the precorneal environment. The viscosity of the ophthalmic composition is less than about 55 mPa/s or less than about 30 mPa/s.

[0078] Examples of viscosity-modifying (enhancing) agents include, but are not limited to carboxymethylcellulose, hyaluronic acid, chondroitin sulfate, polyvinyl alcohol, hydroxypropyl methylcellulose, polylysine, polyacrylic acid, polyacrylamides, N-(2-Hydroxypropyl) methacrylamide (HPMA), xanthan gum, pectins, chitosan, dextran, hydropropylcellulose, hydroethyl cellulose, carrageenan, guar gum, polyoxyl stearate 40, polyvinylpyrrolidone, polyethylene glycol, propylene glycol, combinations thereof and the like.

[0079] Hydroxypropylmethylcellulose (Hypromellose USP). Hydroxypropylmethylcellulose (HPMC) is a partially methylated and O-(2-hydroxypropylated) cellulose derivative. In aqueous ocular formulations HPMC is used in the concentration of 0.45-1.0% w/w (the actual concentration being dependent on the molecular weight of polymer used).

[0080] Poly(vinyl alcohol). This is a water-soluble vinyl polymer that is available in three grades: (1) high-viscosity (average molecular weight 200 000 g/mol); (2) medium-viscosity (average molecular weight 130 000 g/mol); and (3) low-viscosity (average molecular weight 20 000 g/mol). It is used to enhance the viscosity of ocular formulations in concentrations ranging from 0.25% to 3.00% w/w (the actual concentration being dependent on the molecular weight of polymer used).

[0081] Poly(acrylic acid). This is a water-soluble acrylate polymer that is cross-linked with either allyl sucrose or allyl ethers of pentaerythritol. It is predominantly used in ocular aqueous formulations for the treatment of dry-eye syndrome. However, it may be used to increase the viscosity of ocular formulations that contain a therapeutic agent.

[0082] Exemplary preservatives include, but are not limited to benzalkonium chloride, benzethonium chloride, p-oxybenzoates such as methyl p-oxybenzoate or ethyl p-oxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid or salt thereof, citric acid or salt thereof, thimerosal, chlorobutanol, quaternary amine, chlorhexidine gluconate, stabilized oxychloro complex, combinations thereof, and the like. The preservative, if included, will be present in an amount required to pass USP and/or Ph. Eur. antimicrobial preservative effective test required for eye drops.

[0083] Benzalkonium chlorides can be used in ocular solutions/suspensions at a concentration between 0.002% and 0.02% w/v (typically 0.005-0.01% w/v). It is customary to include 0.01-0.1% w/v disodium edetate (disodium EDTA) in ocular formulations in which benzalkonium chloride is used. Benzethonium chloride (unlike benzalkonium chloride) is a pure compound (and not a mixture of compounds). It is commonly used in ophthalmic formulations within the concentration range 0.01-0.02% w/v (although it has been reported to exhibit lower antimicrobial activity than benzalkonium chloride. Esters of parahydroxybenzoates (parabens) can be used. Mixtures of methyl and propyl esters of parahydroxybenzoic acid are used in ophthalmic formulations typically at a combined concentration of 0.2% w/w. Non-irritating (meaning not eye-irritating) organic alcohols can be used as preservatives for ophthalmic formulations: (1) chlorobutanol; and (2) phenylethylalcohol. Chlorobutanol is used in ocular formulations at a concentration of circa 0.5% w/v. Phenylethylalcohol has similar properties to chlorobutanol. The typical concentration used in ophthalmic preparations is 0.25-0.50% v/v. Typical concentration of preservative is within an effective amount required to pass USP and/or Ph. Eur. antimicrobial preservative effective test for eye drops.

[0084] Antioxidant may be added to the ophthalmic composition. As used herein, the term “antioxidant” is intended to mean an agent that inhibits oxidation and thus is used to prevent the deterioration of preparations by the oxidative process. Exemplary antioxidants include, but are not limited to, ascorbic acid, malic acid, citric acid, sodium citrate, butylated hydroxyanisole, butylated hydroxytoluene (BHT), propyl gallate, sodium ascorbate, sodium metabisulfite, sodium bisulfite, amino acids, ascorbyl palmitate, hypophophorous acid, monothioglycerol, propyl gallate, sodium formaldehyde sulfoxylate, and other materials known to one of ordinary skill in the art and mixtures thereof. If present, the amount (concentration) of antioxidant will be sufficient to minimize oxidative degradation of one or more active ingredients.

[0085] Examples of the alkaline agents that may be used as pH adjusting agents, include, but are not limited to sodium hydroxide (NaOH), potassium hydroxide (KOH), tromethamine, monoethanolamine, sodium bicarbonate (NaHCO.sub.3) and other organic and inorganic bases.

[0086] Examples of the acidic agents that may be used as pH adjusting agents include but are not limited to hydrochloric acid (HCl), citric acid, tartaric acid, lactic acid, acetic acid, and other organic and inorganic acids and the like and mixtures thereof.

[0087] Examples of chelating agents include, but are not limited to sodium edetate (EDTA, ethylenediaminetetraacetic acid salt), sodium citrate, condensed sodium phosphate, combinations thereof and the like. The amount of chelating agent(s) typically ranges from about 0.01-0.2% w/v.

[0088] Unless specified otherwise, the term cevimeline is taken to mean the free base form, salt form, or mixture of free base form. and salt form. Unless specified otherwise, the term pilocarpine is taken to mean the free base form, salt form, or mixture of free base form. and salt form. Unless specified otherwise, the term MRA is taken to mean the free base form, salt form, or mixture of free base form. and salt form.

[0089] The following embodiments are specifically contemplated:

[0090] Embodiment 1. A stable aqueous topical ophthalmic composition comprising about 0.1% to 10% of cevimeline at a neutral pH range of pH 6-9, and one or more pharmaceutically acceptable excipients.

[0091] Embodiment 2. The composition of 1, wherein cevimeline is present as the free base form, salt form, or a combination of free base and salt form.

[0092] Embodiment 3. The composition of embodiment 1 or 2, wherein the cevimeline is present at a concentration of about 0.1% to about 10% w/v, about 0.5% to about 5% w/v, or about 0.2% to about 2% w/v.

[0093] Embodiment 4. The composition of any one of the above embodiments further comprising at least one PUFA.

[0094] Embodiment 5. The composition of embodiment 4, wherein the PUFA is present at a concentration of about 0.1%-to about 10% w/v, about 0.5% to about 5% w/v, or about 0.2% to about 2% w/v.

[0095] Embodiment 6. The composition of embodiment 4 or 5, wherein said PUFA comprises about 12 to about 26 carbon atoms per molecule.

[0096] Embodiment 7. The composition of embodiment 4, 5, or 6, wherein said PUFA is selected from the group consisting of omega-3 fatty acid, omega-6 fatty acid, and a mixture thereof.

[0097] Embodiment 8. The composition of embodiment 4, 5, 6, or 7, wherein said PUFA is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), gamma-linolenic acid (GLA), and a mixture thereof.

[0098] Embodiment 9. The composition of any one of the above embodiments further comprising buffering agent, tonicity modifier, and water.

[0099] Embodiment 10. The composition of embodiment 9 optionally further comprising one or more of at least one preservative(s), at least one chelating agent(s), at least one viscosity-modifying agent(s), at least one surfactant(s), at least one solubilizer(s), and/or at least one antioxidant(s).

[0100] Embodiment 11. The composition of any one of the above embodiments, wherein said composition has an osmolality in the range of about 200 to about 400 mOsm/L and a pH in the range of about 6 to about 9.

[0101] Embodiment 12. The composition of any one of the above embodiments further comprising one or more other active ingredient(s) selected from the group consisting of a) at least one steroid; b) at least one immunomodulator (immunosuppressant); c) at least one hormone (androgen); d) a lymphocyte function associated antigen-1 (LFA-1) antagonist; and f) at least one active ingredient effective for treating Meibomian gland dysfunction.

[0102] Embodiment 13. The composition of embodiment 12, wherein a) said steroid is present at a concentration in the range of about 0.1% to about 1% w/v; b) said immunomodulator is present at a concentration in the range of about 0.05% to about 0.1% w/v; c) said hormone is present at a concentration in the range of about 0.01% to about 0.5% w/v; or d) said secretagogue is present at a concentration in the range of about 1% to about 5% w/v; or e) said lymphocyte function associated antigen-1 (LFA-1) antagonist in the range of about 1% to about 5% w/v.

[0103] Embodiment 14. The composition of embodiment 12 or 13, wherein a) said steroid is loteprednol etabonate, prednisolone acetate, fluticasone, or a combination thereof; b) said immunomodulator is cyclosporine, tacrolimus, sirlolimus, or a combination thereof; c) said hormone is testosterone, estrogen, or a combination thereof; d) said secretagogue is rebamipide, diquafosol, or a combination thereof; or e) said lymphocyte function associated antigen-1 (LFA-1) antagonist is lifitegrast.

[0104] Embodiment 15. The composition of any one of the above embodiments, wherein said composition excludes an ointment composition, cream composition, plaster composition, paste composition, and non-aqueous composition.

[0105] Embodiment 16. The composition of any one of the above embodiments, wherein said composition excludes insulin, IGF (insulin-like growth factor), somatomedin C, and cycloplegic agent.

[0106] Embodiment 17. The composition of any one of the above embodiments, wherein cevimeline is replaced with pilocarpine, aceclidine, acetylcholine, bethanechol, carbachol, oxotremorine, or any muscarinic receptor agonist that has therapeutic effect to treat dry eye disease.

[0107] Embodiment 18. An ophthalmically acceptable ion-pair comprising a muscarinic receptor agonist amine drug and a fatty acid component selected from the group consisting of polyunsaturated fatty acids (PUFA) for the treatment of dry eye disease.

[0108] Embodiment 19. The ion-pair of embodiment 18, wherein the molar ratio of PUFA to muscarinic receptor agonist amine drug is in the range of about 2:1 to 1:2, or about 1:1.

[0109] Embodiment 20. The ion-pair of embodiment 18 or 19, wherein a) said PUFA comprises about 12 to about 26 carbon atoms per molecule or a mixture thereof; b) said PUFA is selected from the group consisting of omega-3 fatty acid, omega-6 fatty acid, or a combination thereof; or c) said PUFA is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), gamma-linolenic acid (GLA), or a mixture thereof.

[0110] Embodiment 21. The composition of any one of embodiments 1-17 further comprising the ion-pair of any one of embodiments 18-20.

[0111] Embodiment 22. A method of treating a dry eye disorder, disease or condition comprising topically administering to the eye of a subject in need thereof, a composition according to any one of embodiments 1-17.

[0112] Embodiment 23. A method of treating a dry eye disorder, disease or condition comprising topically administering to the eye of a subject in need thereof, an ion-pair according to any one of embodiments 18-20.

[0113] Exemplary Composition 1A: comprising cevimeline (about 0.1% to about 10.0% w/v), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0114] Exemplary Composition 1B: comprising cevimeline (about 0.1% to about 10.0% w/v), steroid (about 0.1% to about 1% w/v), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0115] Exemplary Composition 1C: comprising cevimeline (about 0.1% to about 10.0% w/v), immunosuppressant (about 0.05% to about 0.1% w/v, or about 0.1 to about 1 mg/mL, or about 0.5 mg/mL), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0116] Exemplary Composition 1D: comprising cevimeline (about 0.1% to about 10.0% w/v), androgen (about 0.01% to about 0.5% w/v), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0117] Exemplary Composition 1E: comprising cevimeline (about 0.1% to about 10.0% w/v), secretagogue (about 1% to about 5% w/v), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0118] Exemplary Composition 1F: comprising cevimeline (about 0.1% to about 10.0% w/v), AARA (about 0.01% to about 0.1% w/v, about 0.025% w/v), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0119] Exemplary Composition 1G: comprising cevimeline (about 0.1% to about 10.0% w/v), PUFA (about 0.1% to about 10.0%), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0120] Exemplary Composition 1H: comprising cevimeline (about 0.1% to about 10.0% w/v), steroid (about 0.1% to about 1% w/v), PUFA (about 0.1% to about 10.0%), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0121] Exemplary Composition 1J: cevimeline (about 0.1% to about 10.0% w/v), immunosuppressant (about 0.05% to about 0.1% w/v, or about 0.1 to about 1 mg/mL, or about 0.5 mg/mL), PUFA (about 0.1% to about 10.0%), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0122] Exemplary Composition 1K: comprising cevimeline (about 0.1% to about 10.0% w/v), androgen (about 0.01% to about 0.5% w/v), PUFA (about 0.1% to about 10.0%), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0123] Exemplary Composition 1 L: comprising cevimeline (about 0.1% to about 10.0% w/v), secretagogue (about 1% to about 5% w/v), PUFA (about 0.1% to about 10.0%), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0124] Exemplary Composition 1M: comprising cevimeline (about 0.1% to about 10.0% w/v), AARA (about 0.01% to about 0.1% w/v, about 0.025% w/v), PUFA (about 0.1% to about 10.0%), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0125] Exemplary Composition 1N: comprising cevimeline (about 0.1% to about 10.0% w/v), lifitegrast (about 1% to 10% w/v, or about 5% w/v), buffering agent, tonicity modifier, and water; osmolality in the range of about 200 to about 400 mOsm/L, pH in the range of about 6 to about 9; optionally further comprising preservative(s), chelating agent(s), viscosity-modifying agent(s), surfactant(s), solubilizer(s), and/or antioxidant(s).

[0126] It should be understood, that compounds used in the art of pharmaceutical formulations generally serve a variety of functions or purposes as an excipient. Thus, if a compound named herein is mentioned only once or is used to define more than one term herein, its purpose or function should not be construed as being limited solely to that named purpose(s) or function(s). For example, citric acid may serve as an antioxidant, chelating agent, buffering agent, preservative or antimicrobial agent.

[0127] As used herein, a “salt” of an active ingredient refers to a pharmaceutically acceptable salt. As used herein, a “pharmaceutically acceptable salt” refer to a combination of the active ingredient and an acid. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the active ingredient, e.g. the MRA. The pharmaceutically acceptable salts include the conventional non-toxic salts formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfonic, sulfamic, phosphoric, nitric and others known to those of ordinary skill; and the salts prepared from organic acids such as amino acids, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and others known to those of ordinary skill. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

[0128] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0129] The amount of therapeutic compound incorporated in each composition (or dosage form(s) containing said composition) will be at least one or more doses and can be selected according to known principles of pharmacy. An effective amount of therapeutic compound is specifically contemplated. By the term “effective amount”, it is understood that, with respect to, for example, pharmaceuticals, a pharmaceutically effective amount is contemplated. A pharmaceutically effective amount is the amount or quantity of active ingredient (drug) which is sufficient to elicit the required or desired therapeutic response, or in other words, the amount which is sufficient to elicit an appreciable biological response when administered to a patient.

[0130] The following examples are provided to further elucidate the advantages and features of the present invention but are not intended to limit the scope of the invention. The examples are for the illustrative purposes only. Pharmaceutical grade ingredients were used in preparing the formulations described below. The quantitative composition of these examples is presented in the table below.

[0131] Formulations comprising cevimeline can be prepared as described in Examples 1 to 4. The following table details the composition of exemplary formulations Cevi-1 through Cevi-8.

TABLE-US-00001 TABLE 1 Composition of exemplary cevimeline-containing aqueous liquid formulations Ingredient (% w/w) Cevi-1 Cevi-2 Cevi-3 Cevi-4 Cevi-5 Cevi-6 Cevi-7 Cevi-8 Cevimeline HCl × 0.5 H.sub.2O 0.6 0.6 0.6 0.6 0.6 0.6 0.2 2 (free base equivalent) Citric Acid, monohydrate 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 Sodium phosphate 0.268 0.268 0.268 0.268 0.268 0.268 0.268 0.268 dibasic heptahydrate pH 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 EDTA 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 NaCl q.s. q.s. 0 0 0 0 q.s. q.s. sorbitol 0 0 q.s. q.s. 0 0 0 0 Trehalose 0 0 0 0 q.s. q.s.. 0 0 BAK 0.005 0.005 0.005 0.005 0.005 0.005 0.005 0.005 Purified Water q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.

[0132] In some embodiments, a formulation of the invention comprises about 0.1 to about 10% w/w of at least MRA free base equivalent (active ingredient), about 10-100 mM of citric acid and/or at least one buffering agent, about 0.01-0.2% w/w of at least one chelating agent ([EDTA]), at least one tonicity modifier (osmotic agent) to adjust to isotonicity range of about 200-400 mOsm, and water (remaining amount to achieve 100% weight balance). Optionally, a preservative present in an amount sufficient to pass the requirements of antimicrobial effective test per USP and/or Ph. Eur. requirement for eye drops may be added.

[0133] The formulations of the invention can be evaluated according to the Schirmer test, tear Break-up Time (TBUT), lissamine green staining (Van Bijsterveld score), corneal fluorescein staining (Oxford scale) and oculopalpebral examination. Suitable tests are also described in the scientific literature.

[0134] The following examples are merely illustrative of some specific embodiments of the invention and should not be construed to define the entire scope of the invention contemplated herein.

Example 1

[0135] Cevimeline compositions Cev-1 and Cevi-2 were prepared as follows. Cevimeline HCl salt was added and dissolved in an aqueous solution containing citric acid and sodium phosphate as buffering agents, sodium chloride as a tonicity agent, benzalkonium chloride as a preservative. Edetate disodium (EDTA) was added at a concentration of 0 or 0.01%. Hydrochloric acid and/or sodium hydroxide was added to adjust the pH to ˜7.4 if necessary. The composition is further sterile filtered through a 0.22 micron filter. The composition prepared as described above was tested for physical appearance, assay, impurity, pH, and osmolality and was also tested for stability at 25° C., 40° C. after 6 months of storage and 60° C. after 3 months of storage. No significant loss of assay and change of test parameters were observed. The formulation was considered as stable when stored at room temperature.

Example 2

[0136] Cevimeline compositions Cev-3 and Cevi-4 were prepared as follows. Cevimeline HCl salt was added and dissolved in an aqueous solution containing citric acid and sodium phosphate as buffering agents, sorbitol as a tonicity agent, benzalkonium chloride as a preservative. Edetate disodium (EDTA) was added at a concentration of 0 to 0.01%. Hydrochloric acid and/or sodium hydroxide was added to adjust the pH to ˜7.4 if necessary. The composition is further sterile filtered through a 0.22 micron filter. The composition prepared as described above was tested for physical appearance, assay, impurity, pH, and osmolality. The composition prepared as described above was tested for physical appearance, assay, impurity, pH, and osmolality and was also tested for stability at 25° C. up to 27 months 40° C. after 6 months and 60° C. after 6 months of storage. No significant loss of assay and change of test parameters were observed. The formulation was considered as stable when stored at room temperature.

Example 3

[0137] Cevimeline compositions Cev-5 and Cevi-6 were prepared as follows. Cevimeline HCl salt was added and dissolved in an aqueous solution containing citric acid and sodium phosphate as buffering agents, trehalose as a tonicity agent, benzalkonium chloride as a preservative. Edetate disodium (EDTA) was added at a concentration of 0 to 0.01%. Hydrochloric acid and/or sodium hydroxide was added to adjust the pH to ˜7.4 if necessary. The composition is further sterile filtered through a 0.22 micron filter. The composition prepared as described above was tested for physical appearance, assay, impurity, pH, and osmolality and was also tested for stability at 25° C. up to 27 months, 40° C. after 6 months and 60° C. after 6 months of storage. No significant loss of assay and change of test parameters were observed. The formulation was considered as stable when stored at room temperature.

Example 4

[0138] Cevimeline compositions Cev-7 and Cevi-8 were prepared as follows. Cevimeline HCl salt was added and dissolved in an aqueous solution at a concentration of 0.2% and 2.0% containing citric acid and sodium phosphate as buffering agents, sodium chloride as a tonicity agent, benzalkonium chloride as a preservative. Edetate disodium (EDTA) was added at a concentration of 0 to 0.01%. Hydrochloric acid and/or sodium hydroxide was added to adjust the pH to ˜7.4 if necessary. The composition is further sterile filtered through a 0.22 micron filter. The composition prepared as described above was tested for physical appearance, assay, impurity, pH, and osmolality and was also tested for stability at 25° C. up to 27 months, 40° C. after 6 months and 60° C. after 6 months of storage. No significant loss of assay and change of test parameters were observed. The formulation was considered as stable when stored at room temperature.

Example 5

[0139] Formulations comprising cevimeline, prepared essentially as described in Examples 1 to 4 herein, were subjected to real time (25° C.) and accelerated (40° C. and 60° C.) stability conditions. HPLC assay was performed to evaluate cevimeline and impurity (degradant) content along with other quality attributes (pH, osmolality and physical appearance). All formulations were found to be stable.

TABLE-US-00002 TABLE 2A Stability of Example Cevimeline Formulations Storage condition 25° C./60% RH Time Time, months Formulation Parameter 0 3 6 10 27 Cevi-1 Assay, % 100.8 99.9 97.4 99.3 99.4 RS, % 0.15 0.17 0.17 0.20 0.05 pH 7.3 7.3 7.4 7.2 7.1 Osmolality, 287 286 291 312 296 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-2 Assay, % 100.6 99.9 100.5 99.8 100.2 RS, % 0.15 0.16 0.17 0.15 — pH 7.4 7.4 7.5 7.3 7.3 Osmolality, 276 279 288 283 295 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-3 Assay, % 102.1 100.7 101.6 100.6 100.8 RS, % 0.14 0.16 0.16 0.16 −0.06 pH 7.3 7.3 7.1 7.1 7.2 Osmolality, 284 296 302 303 306 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-4 Assay, % 102.6 100.8 99.0 100.5 101.2 RS, % 0.15 0.17 0.15 0.14 — pH 7.3 7.2 7.2 7.0 7.3 Osmolality, 296 300 297 303 308 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-5 Assay, % 103.3 102.4 99.3 102.2 102.6 RS, % 0.15 0.18 0.17 0.24 0.4 pH 7.3 7.1 7.1 7.1 7.3 Osmolality, 324 325 334 332 336 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-6 Assay, % 102.3 102.3 95.1 102.3 102.8 RS, % 0.15 0.18 0.16 0.16 — pH 7.3 7.2 7.2 7.2 7.3 Osmolality, 314 329 329 327 338 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-7 Assay, % 97.9 97.6 97.1 97.1 97.1 RS, % 0.17 0.18 0.17 0.18 — pH 7.5 7.4 7.2 7.3 7.2 Osmolality, 270 274 276 281 287 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-8 Assay, % 100.2 102.5 92.0 100.8 96.4 RS, % 0.16 0.18 0.16 0.18 — pH 7.4 7.3 7.4 7.4 7.3 Osmolality, 293 294 301 293 306 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC)

TABLE-US-00003 TABLE 2B Stability of Example Cevimeline Formulations Storage condition 40° C./75% RH Time Time, months Formulation Parameter 0 1 2 3 6 Cevi-1 Assay, % 100.8 99.1 98.8 100.2 98.9 RS, % 0.15 0.14 0.14 0.16 0.27 pH 7.3 7.3 7.5 7.4 7.3 Osmolality, 287 289 292 284 289 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-2 Assay, % 100.6 99.1 100.0 98.5 97.6 RS, % 0.15 0.14 0.14 0.86 0.14 pH 7.4 7.4 7.5 7.5 7.4 Osmolality, 276 290 287 282 284 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-3 Assay, % 102.1 100.4 100.9 101.5 98.5 RS, % 0.14 0.14 0.14 0.15 0.27 pH 7.3 7.3 7.3 7.3 7.3 Osmolality, 284 284 304 298 298 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-4 Assay, % 102.6 100.5 100.2 101.6 98.6 RS, % 0.15 0.13 0.13 0.16 0.16 pH 7.3 7.3 7.4 7.3 7.3 Osmolality, 296 306 299 298 299 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-5 Assay, % 103.3 103.1 103.5 102.6 100.3 RS, % 0.15 0.14 0.14 0.16 0.49 pH 7.3 7.3 7.4 7.3 7.3 Osmolality, 324 337 326 326 329 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-6 Assay, % 102.3 103.6 103.1 103.1 100.4 RS, % 0.15 0.14 0.15 0.16 0.37 pH 7.3 7.2 7.3 7.2 7.1 Osmolality, 314 336 328 332 330 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-7 Assay, % 97.9 98.0 97.8 98.1 96.1 RS, % 0.17 0.15 0.16 0.16 0.16 pH 7.5 7.4 7.5 7.4 7.4 Osmolality, 270 283 277 273 279 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC) Cevi-8 Assay, % 100.2 101.0 101.4 99.2 99.2 RS, % 0.16 0.16 0.16 0.17 0.17 pH 7.4 7.4 7.5 7.5 7.4 Osmolality, 293 298 295 294 295 mOsmol/kg Physical Colourless, CC CC CC CC appearance clear solution (CC)

TABLE-US-00004 TABLE 2C Stability of Example Cevimeline Formulations Storage condition 60° C. Time Time, weeks Formulation Parameter 0 3 6 Cevi-1 Assay, % 100.8 103.0 98.7 RS, % 0.15 0.14 0.13 pH 7.3 7.4 7.4 Osmolality, 287 292 300 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-2 Assay, % 100.6 99.3 98.7 RS, % 0.15 0.13 0.13 pH 7.4 7.5 7.4 Osmolality, 276 292 294 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-3 Assay, % 102.1 100.5 99.3 RS, % 0.14 0.13 0.13 pH 7.3 7.4 7.2 Osmolality, 284 301 301 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-4 Assay, % 102.6 100.5 98.9 RS, % 0.15 0.13 0.13 pH 7.3 7.4 7.2 Osmolality, 296 301 301 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-5 Assay, % 103.3 102.0 99,5 RS, % 0.15 0.20 0.30 pH 7.3 7.3 7.1 Osmolality, 324 330 315 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-6 Assay, % 102.3 102.5 99.9 RS, % 0.15 0.18 0.25 pH 7.3 7.4 7.1 Osmolality, 314 325 333 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-7 Assay, % 97.9 96.4 96.3 RS, % 0.17 0.15 0.16 pH 7.5 7.5 7.3 Osmolality, 270 288 272 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC) Cevi-8 Assay, % 100.2 101.6 99.8 RS, % 0.16 0.15 0.16 pH 7.4 7.4 7.3 Osmolality, 293 299 299 mOsmol/kg Physical Colourless, CC CC appearance clear solution (CC)

Example 6

[0140] Formulations as described herein are evaluated for irritancy by the Draize eye test in rabbits, which is well known in the literature. Repeated instillations with the formulations are well tolerated by the rabbit ocular surface without any obvious signs of toxicity.

Example 7

[0141] A formulation comprising MRA and another active ingredient is prepared according to any one of Examples 1-4 but further including said another active ingredient in an amount (concentration) desired or as described herein.

Example 8

[0142] A PUFA and MRA mixture or ion-pair containing composition is prepared as follows. Cevimeline PUFA formulations are generally prepared as follows. Cevimeline HCl salt is added and dissolved in an aqueous solution containing PUFA to prepare a concentrated cevimeline PUFA mixture. One or more surfactants may be added along with PUFA in this step. The concentrated mixture is homogenized under high shear homogenization to form a translucent to milky mixture. A stock solution containing citric acid and sodium phosphate as buffering agents, sodium chloride as a tonicity agent, benzalkonium chloride as a preservative is then mixed with the ion pair mixture to achieve cevimeline concentration of 0.1% to 10%. Edetate disodium (EDTA) may be added at a concentration of 0.01 to 0.2%. At least one suitable antioxidant may be added. At least one surfactant may be added. At least one viscosity agent may be added in this stock solution. Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH to ˜7.4 if necessary. The composition is sterile filtered through a 0.22 micron filter.

[0143] Accordingly, the aqueous ophthalmic composition of the invention is stable at a neutral pH range.

[0144] All values disclosed herein may have standard technical measure error (standard deviation) of ±10%. The term “about” is intended to mean±10%, ±5%, ±2.5% or ±1% relative to a specified value, i.e. “about” 20% means 20±2%, 20±1%, 20±0.5% or 20±0.25%.

[0145] The above is a detailed description of particular embodiments of the invention. It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims. All of the embodiments disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure.